NASDAQ:EARS - Auris Medical Stock Price, Price Target & More

$1.43 -0.02 (-1.38 %)
(As of 04/20/2018 12:18 PM ET)
Previous Close$1.45
Today's Range$1.41 - $1.45
52-Week Range$1.22 - $9.70
Volume17,862 shs
Average Volume203,442 shs
Market Capitalization$8.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76

About Auris Medical (NASDAQ:EARS)

Auris Medical logoAuris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EARS
CUSIPN/A
Phone41-41-729-7194

Debt

Debt-to-Equity Ratio-2.59%
Current Ratio1.52%
Quick Ratio1.52%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.36) per share
Price / Book-3.97

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-24,800,000.00
Net MarginsN/A
Return on Equity-747.29%
Return on Assets-91.38%

Miscellaneous

Employees24
Outstanding Shares6,120,000

How to Become a New Pot Stock Millionaire

Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

How were Auris Medical's earnings last quarter?

Auris Medical Holding (NASDAQ:EARS) posted its quarterly earnings results on Thursday, March, 22nd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter. View Auris Medical's Earnings History.

When is Auris Medical's next earnings date?

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Auris Medical.

What price target have analysts set for EARS?

1 analysts have issued 1 year target prices for Auris Medical's stock. Their predictions range from $5.00 to $5.00. On average, they expect Auris Medical's share price to reach $5.00 in the next twelve months. View Analyst Ratings for Auris Medical.

Who are some of Auris Medical's key competitors?

Who are Auris Medical's key executives?

Auris Medical's management team includes the folowing people:
  • Dr. Thomas Meyer Ph.D., Founder, Chairman, CEO & MD (Age 50)
  • Mr. Hernan Levett, Chief Financial Officer (Age 42)
  • Ms. Cindy McGee, Head of Investor Relations and Corp. Communications
  • Ms. Andrea Braun-Scherhag, Head of Regulatory & Quality Affairs (Age 51)
  • Ms. Michelle Aarts Ph.D., Adviser

Has Auris Medical been receiving favorable news coverage?

Media stories about EARS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Auris Medical earned a news sentiment score of 0.04 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.33 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $1.43.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $8.69 million. Auris Medical employs 24 workers across the globe.

How can I contact Auris Medical?

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]


MarketBeat Community Rating for Auris Medical (EARS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Auris Medical (NASDAQ:EARS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Auris Medical in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 249.65%. The high price target for EARS is $5.00 and the low price target for EARS is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$4.50$4.50
Price Target Upside: 249.65% upside599.30% upside529.37% upside529.37% upside

Auris Medical (NASDAQ:EARS) Consensus Price Target History

Price Target History for Auris Medical (NASDAQ:EARS)

Auris Medical (NASDAQ:EARS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/1/2017Roth CapitalReiterated RatingBuy$5.00LowView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00HighView Rating Details
11/11/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
6/15/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
6/10/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Auris Medical (NASDAQ:EARS) Earnings History and Estimates Chart

Earnings by Quarter for Auris Medical (NASDAQ:EARS)

Auris Medical (NASDAQ EARS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018        
3/22/2018Q4 2017($1.01)ViewN/AView Earnings Details
11/28/2017Q3 2017($0.20)($0.15)ViewN/AView Earnings Details
8/10/20176/30/2017($0.21)($0.12)ViewN/AView Earnings Details
5/11/20173/31/2017($0.14)($0.22)ViewN/AView Earnings Details
3/14/201712/31/2016($0.29)($0.16)ViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)ViewListenView Earnings Details
8/18/2016Q2 2016($0.26)($0.26)ViewN/AView Earnings Details
5/11/2016Q116($0.23)($0.26)ViewListenView Earnings Details
3/14/2016Q415($0.29)($0.1620)ViewListenView Earnings Details
11/12/2015Q315($0.28)($0.16)ViewListenView Earnings Details
8/19/2015Q215($0.23)($0.36)ViewListenView Earnings Details
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details
9/15/2014Q2 2014($0.34)($0.29)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Auris Medical (NASDAQ:EARS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Auris Medical (NASDAQ EARS) Insider Trading and Institutional Ownership History

Insider Trading History for Auris Medical (NASDAQ:EARS)
Insider Trading History for Auris Medical (NASDAQ:EARS)

Auris Medical (NASDAQ EARS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Auris Medical (NASDAQ EARS) News Headlines

Source:
DateHeadline
Auris Medical Announces Early Repayment of Part of its Loan FacilityAuris Medical Announces Early Repayment of Part of its Loan Facility
finance.yahoo.com - April 17 at 8:17 AM
Published Research Shows Ceragenin CSA-131s Potent Efficacy against Candida auris, a New Serious Global Health ...Published Research Shows Ceragenin CSA-131's Potent Efficacy against Candida auris, a New Serious Global Health ...
www.prnewswire.com - April 6 at 8:15 AM
This Mornings Technical Outlook on Biotech Stocks -- Auris Medical, Anthera Pharma, Aralez Pharma, and Aratana TherapeuticsThis Morning's Technical Outlook on Biotech Stocks -- Auris Medical, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics
www.prnewswire.com - April 3 at 8:11 AM
Blog Exposure - Actinium Announces Collaboration with Astellas PharmaBlog Exposure - Actinium Announces Collaboration with Astellas Pharma
finance.yahoo.com - April 2 at 8:21 AM
Auris Medical Holding (EARS) Reports Compliance with Nasdaqs Minimum Bid Price RequirementAuris Medical Holding (EARS) Reports Compliance with Nasdaq's Minimum Bid Price Requirement
www.streetinsider.com - March 30 at 8:10 AM
Auris Medical (EARS) Rating Increased to Sell at ValuEngineAuris Medical (EARS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Auris updates on development activities; shares up 25%Auris updates on development activities; shares up 25%
seekingalpha.com - March 24 at 5:23 PM
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 22 at 5:45 PM
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsAuris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 22 at 5:45 PM
Auris reports 4Q lossAuris reports 4Q loss
finance.yahoo.com - March 22 at 5:45 PM
Auris Medical Provides Business Update - GlobeNewswire (press release)Auris Medical Provides Business Update - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:17 AM
BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC FilingBRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing
www.reuters.com - March 13 at 7:26 PM
Auris Medical Holding (EARS) Says TACTT3 Clinical Trial with Keyzilen Did Not Meet Primary EndpointAuris Medical Holding (EARS) Says TACTT3 Clinical Trial with Keyzilen Did Not Meet Primary Endpoint
www.streetinsider.com - March 13 at 7:26 PM
Auris Medical Provides Business UpdateAuris Medical Provides Business Update
finance.yahoo.com - March 13 at 7:26 PM
What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?
finance.yahoo.com - February 28 at 8:07 AM
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018 - GlobeNewswire (press release)Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018 - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:09 AM
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
finance.yahoo.com - February 26 at 5:51 PM
Technical Perspectives on Biotech Stocks -- Argos Therapeutics, Array BioPharma, Aurinia Pharma, and Auris Medical - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- Argos Therapeutics, Array BioPharma, Aurinia Pharma, and Auris Medical - PR Newswire (press release)
www.prnewswire.com - February 22 at 8:12 AM
Contrasting Ariad Pharmaceuticals (ARIA) & Auris Medical (EARS)Contrasting Ariad Pharmaceuticals (ARIA) & Auris Medical (EARS)
www.americanbankingnews.com - February 9 at 3:26 PM
Auris Medical (EARS) Says New Data Highlights Superior Bioavailability of AM-125 Compared to Oral BetahistineAuris Medical (EARS) Says New Data Highlights Superior Bioavailability of AM-125 Compared to Oral Betahistine
www.streetinsider.com - February 9 at 8:53 AM
Auris Medical Announces Extraordinary General Meeting of ShareholdersAuris Medical Announces Extraordinary General Meeting of Shareholders
finance.yahoo.com - February 9 at 8:53 AM
Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral BetahistineAuris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine
feeds.benzinga.com - February 7 at 10:06 AM
Auris Medical Holding (EARS) Prices $5.5M Registered Direct Offering of Common Stock, Warrants - StreetInsider.comAuris Medical Holding (EARS) Prices $5.5M Registered Direct Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - January 31 at 8:43 AM
Reviewing Auris Medical (EARS) and Audentes Therapeutics (BOLD)Reviewing Auris Medical (EARS) and Audentes Therapeutics (BOLD)
www.americanbankingnews.com - January 31 at 3:44 AM
Proteon Therapeutics (PRTO) versus Auris Medical (EARS) Head to Head ContrastProteon Therapeutics (PRTO) versus Auris Medical (EARS) Head to Head Contrast
www.americanbankingnews.com - January 12 at 7:04 PM
Auris Medical (EARS) & Its Competitors Critical ReviewAuris Medical (EARS) & Its Competitors Critical Review
www.americanbankingnews.com - January 9 at 7:32 AM
Auris Medical Provides Update on AM-111 Development Program - GlobeNewswire (press release)Auris Medical Provides Update on AM-111 Development Program - GlobeNewswire (press release)
globenewswire.com - January 5 at 9:53 AM
Auris Medical Provides Update on AM-111 Development ProgramAuris Medical Provides Update on AM-111 Development Program
finance.yahoo.com - January 4 at 9:45 AM
Be All Ears: Auris To Provide Update On AM-111 On Jan.4Be All Ears: Auris To Provide Update On AM-111 On Jan.4
www.nasdaq.com - January 1 at 9:42 AM
Auris Medical Holding AG (EARS) Short Interest Up 86.3% in DecemberAuris Medical Holding AG (EARS) Short Interest Up 86.3% in December
www.americanbankingnews.com - December 31 at 4:22 AM
Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday ... - GlobeNewswire (press release)Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday ... - GlobeNewswire (press release)
globenewswire.com - December 28 at 3:44 PM
Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018
finance.yahoo.com - December 28 at 3:44 PM
Global Vertigo Market: Industry Analysis & Outlook 2017-2021: Major Players are Auris Medical, Sensorion, Otonomy and Sound Pharmaceuticals - Research and MarketsGlobal Vertigo Market: Industry Analysis & Outlook 2017-2021: Major Players are Auris Medical, Sensorion, Otonomy and Sound Pharmaceuticals - Research and Markets
www.businesswire.com - December 20 at 9:49 AM
Auris Medical (EARS) versus Its Rivals Head to Head ReviewAuris Medical (EARS) versus Its Rivals Head to Head Review
www.americanbankingnews.com - December 17 at 1:28 PM
Auris Medical Holding AG (EARS) Short Interest Down 31.3% in NovemberAuris Medical Holding AG (EARS) Short Interest Down 31.3% in November
www.americanbankingnews.com - December 16 at 3:42 AM
Contrasting Auris Medical (EARS) & The CompetitionContrasting Auris Medical (EARS) & The Competition
www.americanbankingnews.com - December 14 at 5:40 PM
Who Really Owns Auris Medical Holding AG (EARS)?Who Really Owns Auris Medical Holding AG (EARS)?
finance.yahoo.com - December 8 at 5:00 PM
Pre-market Technical Scan on Biotech Equities -- Viking Therapeutics, RXi Pharma, Kitov Pharma, and Auris Medical - PR Newswire (press release)Pre-market Technical Scan on Biotech Equities -- Viking Therapeutics, RXi Pharma, Kitov Pharma, and Auris Medical - PR Newswire (press release)
www.prnewswire.com - December 4 at 5:05 PM
Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - BenzingaMid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - Benzinga
www.benzinga.com - November 29 at 5:25 PM
Auris Medical Holding (EARS) Announces Top-Line Results from ... - StreetInsider.comAuris Medical Holding (EARS) Announces Top-Line Results from ... - StreetInsider.com
www.streetinsider.com - November 29 at 5:25 PM
Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - NasdaqMid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - Nasdaq
www.nasdaq.com - November 29 at 9:54 AM
EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark - NasdaqEARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark - Nasdaq
www.nasdaq.com - November 29 at 9:54 AM
Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 29 at 9:54 AM
[$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments[$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments
finance.yahoo.com - November 29 at 9:54 AM
Edited Transcript of EARS earnings conference call or presentation 28-Nov-17 1:00pm GMTEdited Transcript of EARS earnings conference call or presentation 28-Nov-17 1:00pm GMT
finance.yahoo.com - November 29 at 9:54 AM
Auris Medical (EARS) Announces Quarterly  Earnings Results, Beats Expectations By $0.06 EPSAuris Medical (EARS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - November 28 at 9:48 PM
Auris Medical Holding (EARS) Tops Q3 EPS by 3cAuris Medical Holding (EARS) Tops Q3 EPS by 3c
www.streetinsider.com - November 28 at 5:02 PM
UPDATE 2-Auris Medical shares plunge as deafness drug trial scrappedUPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped
www.reuters.com - November 28 at 5:02 PM
Here’s What Triggered Auris Medical Holding AG (EARS) SelloffHere’s What Triggered Auris Medical Holding AG (EARS) Selloff
finance.yahoo.com - November 28 at 5:02 PM
Auris Medical Holding AG (EARS) Expected to Post Earnings of -$0.20 Per ShareAuris Medical Holding AG (EARS) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 28 at 11:14 AM

SEC Filings

Auris Medical (NASDAQ:EARS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Auris Medical (NASDAQ:EARS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Auris Medical (NASDAQ EARS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.